TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02892097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive task-specific practice (RTP)
Description: Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
Study: NCT04960943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib with or without trastuzumab
Description: After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
Study: NCT02569775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Transplantation of Autologous Bone Marrow Mononuclear Cells
Study: NCT02892097

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive task-specific practice (RTP)
Description: Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Repetitive task-specific practice (RTP)
Description: Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
Study: NCT02307305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone
Description: Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone
Description: Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
Study: NCT04450901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of Administration: IV infusion; 0.5 mg/kg Q2W
Study: NCT04039828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)
Description: Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
Study: NCT03561285

Intervention type: DIAGNOSTIC_TEST
Intervention: antiphospholipid Abs
Description: Laboratory test

Intervention type: DIAGNOSTIC_TEST
Intervention: antiphospholipid Abs
Description: Laboratory test
Study: NCT04097717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Decision tubal sterilization decision aid
Description: The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual medical care will vary among participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual medical care will vary among participants.
Study: NCT04450901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of Administration: IV infusion; 2 mg/kg Q2W
Study: NCT00902161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK0893
Description: Single dose of MK0893 1000 mg (ten 100 mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0893
Description: Single dose of MK0893 1000 mg (ten 100 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK0893-matched Placebo
Description: Single dose of placebo to MK0893 (ten tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0893-matched Placebo
Description: Single dose of placebo to MK0893 (ten tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol Hydrochloride (HCL)
Description: Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride (HCL)
Description: Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
Study: NCT00848575

Intervention type: DEVICE
Intervention: Flexible Endoscope
Study: NCT02931591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is administered as an oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: Growth Hormone- no specific band

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Growth Hormone
Description: Growth Hormone- no specific band

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02295891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiraDry ®
Description: Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
Study: NCT00607360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Workplace Intervention
Description: Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
Study: NCT03303339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: intravenously
Study: NCT00083824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens, Conjugated (USP)
Description: 0.625 mg/day QID for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogens, Conjugated (USP)
Description: 0.625 mg/day QID for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone 17-Acetate
Description: 2.5 mg/day QID for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 pills/day QID for 3 years
Study: NCT00765869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel cancer screening decision aid
Description: A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel cancer screening decision aid
Description: A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Australian Government Bowel Cancer Screening booklet
Description: A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
Study: NCT04450901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of Administration: IV infusion; 5 mg/kg Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of Administration: IV infusion; 10 mg/kg Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of administration : IV infusion, 200 mg Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of administration : IV infusion, 300 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of administration : IV infusion, 300 mg Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YBL-006
Description: Route of administration : IV infusion, 200mg Q2W
Study: NCT00926900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: 50 mg at approximately 1.5 hours prior to cue-exposure training sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02806193

Intervention type: PROCEDURE
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement.
Study: NCT02769260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Normal toothbrushing without toothpaste or antiseptic mouthwash.
Study: NCT05607836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntuBrite intubation
Description: Use of new laryngoscope IntuBrite for intubation in patients with cardiopulmonary arrest and during resuscitation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Use of standard Macintosh blade laryngoscope for intubation in patients with cardiac arrest and requiring cardiopulmonary resuscitation
Study: NCT03768401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial Exercise Modalities
Description: Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
Study: NCT01288378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caspofungin acetate
Description: intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
Study: NCT03548090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skateboard exercise at an incline angle of 0 degrees and 50% body weight
Description: Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
Study: NCT00968630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study: NCT03397641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBI-3000
Description: Small molecule, multi-ion channel blocker

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT04294160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Capsule for oral use
Study: NCT01288378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin acetate
Description: intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
Study: NCT01233635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no drug
Description: none, no drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: start cozaar
Description: start cozaar
Study: NCT00306891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 45 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 45 mg oral dose
Study: NCT01233635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continue cozaar
Description: continue cozaar
Study: NCT00306891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 45 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib 30 - 90 mg
Description: oral tablet dose escalation
Study: NCT04245046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan, Amlodipine, Atorvastatin
Description: compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
Study: NCT02661854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 5.000 subcutaneous
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 10.000 subcutaneous
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 30.000 subcutaneous
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 50.000 subcutaneous
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 5.000 sublingual
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 10.000 sublingual
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 30.000 sublingual
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MM09 Mannosylated 50.000 sublingual
Description: Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group
Study: NCT00109512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-56418 (GnRH antagonist)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04039230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
Study: NCT02661854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sublingual placebo
Description: Comparison between placebo and active group

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual placebo
Description: Comparison between placebo and active group
Study: NCT03439696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgery
Description: Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic surgery
Description: Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
Study: NCT01020565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
Study: NCT02266329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin hydrochloride
Description: Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.